Skip to content

S. 932 · 119th Congress (2025–2027)

Give Kids a Chance Act of 2025

This bill authorizes certain targeted clinical trials involving combinations of drugs to treat pediatric cancer, and renews the Food and Drug Administration’s (FDA’s) authority to award priority review vouchers (PRVs) to sponsors of new products for rare pediatric diseases.

Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs used in combination with active ingredients that have already been approved and that (1) have been determined to be part of the standard of care for treating a pediatric cancer, or (2) have been approved to treat an adult cancer and are directed at molecular targets for pediatric cancer.

The FDA must issue guidance on the implementation of these provisions and report to Congress on its efforts to ensure implementation. The Government Accountability Office (GAO) must report on the effectiveness of the bill's changes with respect to the development of pediatric cancer drugs.

The bill also renews the FDA’s authority to issue PRVs to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029. This is known as the Rare Pediatric Disease PRV program. The program expired in December 2024.

GAO must report on the effectiveness of the Rare Pediatric Disease PRV program, including to what extent PRVs were successful in promoting drug development and expediting patient access to drugs for the treatment or prevention of rare pediatric diseases.

Show official title

A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is S. 932’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. Markwayne Mullin (R-OK)
Cosponsors
20 cosponsors

1 original · 19 later

10 R · 10 D

  1. Sen. Michael F. Bennet (D-CO)· Original · Mar 11, 2025
  2. Sen. Amy Klobuchar (D-MN)· Later · Apr 4, 2025
  3. Sen. Roger Marshall (R-KS)· Later · Apr 4, 2025
  4. Sen. Jeanne Shaheen (D-NH)· Later · Apr 4, 2025
  5. Sen. Susan M. Collins (R-ME)· Later · Apr 8, 2025
  6. Sen. Rick Scott (R-FL)· Later · Apr 8, 2025
  7. Sen. Shelley Moore Capito (R-WV)· Later · Oct 23, 2025
  8. Sen. Christopher A. Coons (D-DE)· Later · Oct 23, 2025
  9. Sen. Jon Husted (R-OH)· Later · Oct 23, 2025
  10. Sen. Mark Kelly (D-AZ)· Later · Oct 23, 2025
  11. Sen. Andy Kim (D-NJ)· Later · Oct 23, 2025
  12. Sen. Tim Sheehy (R-MT)· Later · Oct 23, 2025
  13. Sen. John W. Hickenlooper (D-CO)· Later · Oct 30, 2025
  14. Sen. Ashley Moody (R-FL)· Later · Oct 30, 2025
  15. Sen. John Boozman (R-AR)· Later · Nov 6, 2025
  16. Sen. Tammy Duckworth (D-IL)· Later · Nov 6, 2025
  17. Sen. John Kennedy (R-LA)· Later · Nov 18, 2025
  18. Sen. Jack Reed (D-RI)· Later · Nov 18, 2025
  19. Sen. Adam B. Schiff (D-CA)· Later · Nov 18, 2025
  20. Sen. Eric Schmitt (R-MO)· Later · Nov 19, 2025
Policy area
Health

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Mar 11, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (2)
  1. Give Kids a Chance Act of 2025

    Display title, Short title · Introduced in Senate

  2. A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes.

    Official title · Introduced in Senate